Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC/MM vaccine and nivolumab in relapsed multiple myeloma
NCT03782064Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Feb 2019
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial in multiple myeloma (MM), sponsored by Beth Israel Deaconess Medical Center. Started Feb 2019; status: terminated.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03782064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782064.